June 24, 2024

Glenmark issues voluntary nationwide recall of potassium chloride extended-release 750 mg capsules

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **PrimeTherapeutics.com/DrugRecalls** to review the latest FDA drug recalls.

About this recall:

Glenmark is voluntarily recalling 114 batches of potassium chloride extended-release (ER) capsules in the strength of 750 mg, which is equivalent to 10 mEq of potassium. The recall is to the consumer level due to failed dissolution.

Potassium chloride ER capsules are used for the treatment of patients with low potassium (hypokalemia) and are packaged in bottles of 100-count (NDC 68462-0357-01) and 500-count (NDC 68462-0357-05) capsules.

What this means to you:

If the potassium chloride ER capsules do not dissolve properly, high potassium levels (hyperkalemia) may occur, which can result in irregular heartbeat that can lead to cardiac arrest. For patients who require chronic use of potassium chloride, especially in those with underlying conditions (high blood pressure, heart failure or kidney dysfunction), the potential exists for high potassium levels to result in serious adverse events such as heart arrythmias, severe muscle weakness or death. To date, the company has not received any reports of hyperkalemia or serious events from sources related to this recall.

Consumers that have potassium chloride ER capsules with a recalled NDC and lot number should consult with their health care professional (HCP) before they stop using the product. For return instructions and further information, consumers should call Inmar Rx Solutions at **877.883.9273**, Monday–Friday, 9 a.m. to 5 p.m. Eastern Standard Time (EST).